Meta-analysis of Danhong Injection in treatment of diabetes mellitus complicated with coronary heart disease.
10.19540/j.cnki.cjcmm.20200701.501
- Author:
Shuang TANG
1
;
Dan ZHANG
1
;
Shuang HAN
1
;
Ya-Hong CHEN
2
;
Bao-Nan MA
1
;
Chuan-Xin LIU
1
;
Chen-Ning ZHANG
3
Author Information
1. School of Traditional Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100029, China.
2. State Key Laboratory of Antitoxic Drugs and Toxicology, Beijing Key Laboratory of Neuropsychopharmacology, Institute of Toxicology, Academy of Military Medicine, Academy of Military Sciences Beijing 100850, China.
3. School of Traditional Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100029, China Institute of Wudang Traditional Chinese Medicine, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine Shiyan 442000, China.
- Publication Type:Meta-Analysis
- Keywords:
Danhong Injection;
Meta-analysis;
diabetes mellitus complicated with coronary heart disease;
efficacy;
safety
- MeSH:
Angina Pectoris;
Coronary Disease/drug therapy*;
Diabetes Mellitus;
Drugs, Chinese Herbal;
Humans
- From:
China Journal of Chinese Materia Medica
2021;46(1):237-246
- CountryChina
- Language:Chinese
-
Abstract:
To systematically evaluate the clinical efficacy and safety of Danhong Injection combined with conventional therapy in improving diabetes mellitus complicated with coronary heart disease. Based on the online literature database(CNKI, Wanfang, VIP, PubMed, Web of Science, Cochran Library), the Chinese and English papers about the randomized controlled trial(RCT) of Danhong Injection in the treatment of diabetes mellitus complicated with coronary heart disease were searched comprehensively from the establishment of the databases to January 1, 2020. The papers were screened strictly according to the inclusion and exclusion criteria. Based on Jadad scale, the risk assessment of literature was carried out, and Meta-analysis was performed by STATA 12.0 software. Seventeen RCTs were included, involving 1 453 patients. The results of Meta-analysis showed that the combination of Danhong Injection and conventio-nal treatment could improve the clinical comprehensive effective rate(RR=1.47, 95%CI[1.38, 1.58], P<0.000 1), electrocardiogram(ECG) efficiency(RR=1.30, 95%CI[1.16, 1.46], P<0.000 1), efficiency of the angina pectoris(RR=1.41, 95%CI[1.25, 1.58], P<0.000 1), cholesterol level(SMD=-1.05, 95%CI[-1.95,-0.16], P=0.02), low-density lipoprotein(LDL) level(SMD=-0.50, 95%CI[-0.79,-0.21], P<0.000 1), coronary angina attack frequency(SMD=-3.71, 95%CI[-4.05,-3.36], P<0.000 1) and duration of angina pectoris(SMD=-2.96, 95%CI[-3.25,-2.66], P<0.000 1), with statistically significant differences. But the differences in fasting plasma glucose(FPG)(SMD=-0.19, 95%CI[-0.45, 0.08], P=0.16), plasma glucose of two hours after meal(2 hPG)(SMD=0.19, 95%CI[-0.11, 0.49], P=0.22), and high-density lipoprotein(HDL) level(SMD=0.10, 95%CI[-0.30, 0.49], P=0.62) after treatment were not statistically significant. Compared with the control group, there was no significant difference in adverse reactions(SMD=-2.96, 95%CI[-3.25,-2.66], P=0.75). The existing evidence shows that the combination of Western medicine and Danhong Injection can improve the clinical effect for diabetes mellitus complicated with coronary heart disease and has no obvious adverse reactions. However, due to the low level of overall literature evidence, high risk and some kind of publication bias, it still needs more high-quality randomized controlled trials and low-bias studies for further verification.
